First Time Loading...

Regenxbio Inc
NASDAQ:RGNX

Watchlist Manager
Regenxbio Inc Logo
Regenxbio Inc
NASDAQ:RGNX
Watchlist
Price: 16.11 USD -5.4% Market Closed
Updated: Apr 19, 2024

Intrinsic Value

RGNX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. [ Read More ]

The intrinsic value of one RGNX stock under the Base Case scenario is 32.33 USD. Compared to the current market price of 16.11 USD, Regenxbio Inc is Undervalued by 50%.

Key Points:
RGNX Intrinsic Value
Base Case
32.33 USD
Undervaluation 50%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Regenxbio Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling RGNX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Regenxbio Inc

Provide an overview of the primary business activities
of Regenxbio Inc.

What unique competitive advantages
does Regenxbio Inc hold over its rivals?

What risks and challenges
does Regenxbio Inc face in the near future?

Has there been any significant insider trading activity
in Regenxbio Inc recently?

Summarize the latest earnings call
of Regenxbio Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Regenxbio Inc.

Provide P/S
for Regenxbio Inc.

Provide P/E
for Regenxbio Inc.

Provide P/OCF
for Regenxbio Inc.

Provide P/FCFE
for Regenxbio Inc.

Provide P/B
for Regenxbio Inc.

Provide EV/S
for Regenxbio Inc.

Provide EV/GP
for Regenxbio Inc.

Provide EV/EBITDA
for Regenxbio Inc.

Provide EV/EBIT
for Regenxbio Inc.

Provide EV/OCF
for Regenxbio Inc.

Provide EV/FCFF
for Regenxbio Inc.

Provide EV/IC
for Regenxbio Inc.

Show me price targets
for Regenxbio Inc made by professional analysts.

What are the Revenue projections
for Regenxbio Inc?

How accurate were the past Revenue estimates
for Regenxbio Inc?

What are the Net Income projections
for Regenxbio Inc?

How accurate were the past Net Income estimates
for Regenxbio Inc?

What are the EPS projections
for Regenxbio Inc?

How accurate were the past EPS estimates
for Regenxbio Inc?

What are the EBIT projections
for Regenxbio Inc?

How accurate were the past EBIT estimates
for Regenxbio Inc?

Compare the revenue forecasts
for Regenxbio Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Regenxbio Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Regenxbio Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Regenxbio Inc compared to its peers.

Compare the P/E ratios
of Regenxbio Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Regenxbio Inc with its peers.

Analyze the financial leverage
of Regenxbio Inc compared to its main competitors.

Show all profitability ratios
for Regenxbio Inc.

Provide ROE
for Regenxbio Inc.

Provide ROA
for Regenxbio Inc.

Provide ROIC
for Regenxbio Inc.

Provide ROCE
for Regenxbio Inc.

Provide Gross Margin
for Regenxbio Inc.

Provide Operating Margin
for Regenxbio Inc.

Provide Net Margin
for Regenxbio Inc.

Provide FCF Margin
for Regenxbio Inc.

Show all solvency ratios
for Regenxbio Inc.

Provide D/E Ratio
for Regenxbio Inc.

Provide D/A Ratio
for Regenxbio Inc.

Provide Interest Coverage Ratio
for Regenxbio Inc.

Provide Altman Z-Score Ratio
for Regenxbio Inc.

Provide Quick Ratio
for Regenxbio Inc.

Provide Current Ratio
for Regenxbio Inc.

Provide Cash Ratio
for Regenxbio Inc.

What is the historical Revenue growth
over the last 5 years for Regenxbio Inc?

What is the historical Net Income growth
over the last 5 years for Regenxbio Inc?

What is the current Free Cash Flow
of Regenxbio Inc?

Financials

Balance Sheet Decomposition
Regenxbio Inc

Current Assets 335m
Cash & Short-Term Investments 275.3m
Receivables 24.8m
Other Current Assets 34.9m
Non-Current Assets 239m
Long-Term Investments 38.9m
PP&E 192.6m
Other Non-Current Assets 7.5m
Current Liabilities 130.3m
Accounts Payable 22.8m
Accrued Liabilities 56.8m
Other Current Liabilities 50.7m
Non-Current Liabilities 132m
Other Non-Current Liabilities 132m
Efficiency

Earnings Waterfall
Regenxbio Inc

Revenue
90.2m USD
Cost of Revenue
-37.2m USD
Gross Profit
53m USD
Operating Expenses
-321.2m USD
Operating Income
-268.1m USD
Other Expenses
4.6m USD
Net Income
-263.5m USD

Free Cash Flow Analysis
Regenxbio Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

RGNX Profitability Score
Profitability Due Diligence

Regenxbio Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Negative 1-Year Revenue Growth
Declining ROE
19/100
Profitability
Score

Regenxbio Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

RGNX Solvency Score
Solvency Due Diligence

Regenxbio Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
53/100
Solvency
Score

Regenxbio Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RGNX Price Targets Summary
Regenxbio Inc

Wall Street analysts forecast RGNX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RGNX is 40.63 USD with a low forecast of 21.21 USD and a high forecast of 57.75 USD.

Lowest
Price Target
21.21 USD
32% Upside
Average
Price Target
40.63 USD
152% Upside
Highest
Price Target
57.75 USD
258% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

RGNX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

RGNX Price
Regenxbio Inc

1M 1M
-28%
6M 6M
+1%
1Y 1Y
-16%
3Y 3Y
-52%
5Y 5Y
-68%
10Y 10Y
-27%
Annual Price Range
16.11
52w Low
12.17
52w High
24.61
Price Metrics
Average Annual Return -16.53%
Standard Deviation of Annual Returns 21.99%
Max Drawdown -78%
Shares Statistics
Market Capitalization 790.1m USD
Shares Outstanding 49 042 700
Percentage of Shares Shorted 10.11%

RGNX Return Decomposition
Main factors of price return

What is price return decomposition?

RGNX News

Other Videos

Company Profile

Regenxbio Inc Logo
Regenxbio Inc

Country

United States of America

Industry

Biotechnology

Market Cap

790.1m USD

Dividend Yield

0%

Description

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company is headquartered in Rockville, Maryland and currently employs 372 full-time employees. The company went IPO on 2015-09-17. The Company’s gene therapy product candidates are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates use adeno-associated virus (AAV) vectors from its gene delivery platform, called NAV Technology Platform. Its product candidate includes RGX-314, RGX-111, RGX-121, RGX-202, RGX 181 and RGX-381. RGX-314 is meant for the treatment of wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR) and other anti-VEGF treated conditions. The company is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II). RGX-202 is its product candidate for the treatment of duchenne muscular dystrophy (DMD).

Contact

MARYLAND
Rockville
9804 Medical Center Drive
+12405528181.0
http://regenxbio.com/

IPO

2015-09-17

Employees

372

Officers

President, CEO & Director
Mr. Kenneth T. Mills
Executive VP & CFO
Mr. Vittal K. Vasista
Executive VP & COO
Mr. Curran M. Simpson M.S.
Executive VP & Chief Scientific Officer
Dr. Olivier Danos Ph.D.
Executive VP & Chief Medical Officer
Dr. Stephen Pakola M.D.
Executive VP & Chief Legal Officer
Mr. Patrick J. Christmas II, J.D.
Show More
Chief Communications & People Officer
Ms. Shiva G. Fritsch
Executive Vice President of Intellectual Property
Dr. Laura A. Coruzzi J.D., Ph.D.
Executive VP of Commercial Strategy & Operations
Dr. Ram Palanki Pharm.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one RGNX stock?

The intrinsic value of one RGNX stock under the Base Case scenario is 32.33 USD.

Is RGNX stock undervalued or overvalued?

Compared to the current market price of 16.11 USD, Regenxbio Inc is Undervalued by 50%.